Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for relapse prevention in TRD
NCT02493868Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Started Oct 2015; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT02493868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493868.